NCT04634435: Phase 1/2: Auto Memory-like NK Cell + BHV-1100 (Formerly KP1237), Low Dose IL-2 in NDMM
Updated: Sep 16, 2022
NCT04634435: Phase 1/2: Autologous Memory-like NK Cell Therapy With BHV-1100 (Formerly KP1237), Low Dose IL-2 in Multiple Myeloma Patients
Newly diagnosed Multiple Myeloma
NDMM
Autologous Memory-like NK Cell Therapy With BHV-1100 (Formerly KP1237), Low Dose IL-2 in Multiple Myeloma Patients
This is an open-label single center Phase 1a/1b study with the primary objective of establishing the safety and exploring the efficacy of infusing the ex vivo combination product of cytokine induced memory-like (CIML) NK cells plus KP1237 and low dose IL-2 in newly diagnosed MM patients who have minimal residual disease (MRD+) in first remission prior to autologous stem cell transplant (ASCT).
Sponsor
Collaborator
Locations
United States, Massachusetts
Dana Farber Cancer Institute
ClinicalTrials.gov Identifier: NCT04634435
Official Title: Phase 1 Study of Autologous Memory-like NK Cell Immunotherapy in Combination With KP1237 and Low Dose IL-2 as Early Post Autologous Transplant Consolidation in Minimal Residual Disease Positive, Newly Diagnosed Multiple Myeloma Patients
First Posted : November 18, 2020
Click here to see details on ClinicalTrials.gov
Combination Product: CIML NK Cells plus KP1237 and low dose IL-2
CD38-targeting Antibody Recruiting Molecule KP1237 (Code C176834)
ARM KP1237
CD38-ARM KP1237
CD38-targeting Antibody Recruiting Molecule KP1237
CD38-targeting Antibody Redirecting Molecule KP1237
CD38-targeting ARM KP1237
KP 1237
KP-1237
KP1237
BIOHAVEN ENROLLS PHASE 1A/1B CLINICAL TRIAL OF BHV-1100, LEAD ASSET FROM ITS ARM™ (ANTIBODY RECRUITING MOLECULE) PLATFORM, IN COMBINATION WITH NK CELL THERAPY FOR THE TREATMENT OF MULTIPLE MYELOMA
NEW HAVEN, Conn., Oct. 27, 2021 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN), announced the enrollment of the first patient in a Phase 1a/1b trial in Multiple Myeloma using the ARM, BHV-1100, in combination with autologous cytokine induced memory-like (CIML) natural killer (NK) cells and immunoglobulin (Ig) to target and kill multiple myeloma cells expressing the cell surface protein CD38.
Location
United States, Massachusetts